Tempest Therapeutics to Present at Global Investment Conference
Tempest Therapeutics, Inc. (NASDAQ: TPST), an innovative clinical-stage biotechnology company dedicated to developing cutting-edge cancer therapies, is preparing to share important updates at the H.C. Wainwright 26th Annual Global Investment Conference.
Presentation Insights
Dr. Sam Whiting, the chief medical officer and head of research and development at Tempest, will be at the forefront of the presentation. This session will explore the company’s latest progress in targeted and immune-mediated therapeutics, which are aimed at improving treatment outcomes for patients facing various types of cancer.
On-Demand Viewing Opportunity
Starting Monday, the presentation will be available for on-demand viewing, allowing investors and stakeholders to gain valuable insights into Tempest’s initiatives at their convenience. It will be accessible through the investor relations section of Tempest’s official website.
About Tempest Therapeutics
Tempest Therapeutics was founded with the goal of transforming cancer care. The company is dedicated to building a strong pipeline of small molecule candidates that utilize tumor-targeted and immune-mediated strategies. Their ongoing research spans from early-stage programs to advanced global studies involving first-line cancer patients, showcasing their commitment to diverse treatment approaches.
Research and Development Focus
Tempest is currently advancing several groundbreaking programs that investigate various mechanisms of action to tackle difficult tumors. With a dynamic portfolio, the company is continually seeking innovative solutions to enhance the therapeutic landscape for cancer treatments.
Contact Information for Investors and Media
For any inquiries related to investor relations or media, Sylvia Wheeler and Aljanae Reynolds from Wheelhouse Life Science Advisors are available via their respective email addresses. Their expertise is crucial in facilitating communication between the company and its stakeholders.
Frequently Asked Questions
What is Tempest Therapeutics focusing on?
Tempest Therapeutics is committed to developing innovative cancer therapies through targeted and immune-mediated approaches.
When can the presentation be viewed?
The presentation will be available for on-demand viewing starting Monday at 7:00 a.m. ET.
Who is leading the presentation at the conference?
Dr. Sam Whiting, the chief medical officer and head of R&D, will lead the presentation on Tempest's latest developments.
What is the mission of Tempest Therapeutics?
The mission of Tempest Therapeutics is to revolutionize cancer care with a diverse pipeline of innovative therapies.
How can I get in touch with investor relations?
Investor inquiries can be directed to Sylvia Wheeler or Aljanae Reynolds at Wheelhouse Life Science Advisors via their email addresses.